Low-dose skin radiation to treat early fungal skin cancer
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 3 study tests a low-dose skin radiation treatment (electron beam) to help eradicate the harmful cancer cells in early-stage mycosis fungoides. It may be an option if you have stage IB or IIA disease and can safely undergo the required light/radiation preparation steps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have confirmed mycosis fungoides in stage IB or IIA
- You can move and hold the treatment position for the session (if you can’t, you may not qualify)
- Your overall health and daily functioning are not too limited (WHO score 2 or less)
- You have not had dose-limiting radiation or dose-limiting light therapy to the same kind of area before
- You are not pregnant or breastfeeding, and you do not have a medical reason you cannot take methoxsalen
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether ultra low-dose radiation can control specific skin lesions from mycosis fungoides (a type of lymphoma that affects the skin). It may help shrink or control targeted spots while using a lower radiation amount.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This Phase 1 study tests whether the medicine bexarotene combined with radiotherapy can shrink or control mycosis fungoides, a skin lymphoma. It also looks at how safe the combination is and how the body handles the treatment.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This early-stage study tests whether a cancer-killing cream (imiquimod) combined with targeted local radiation can shrink and control mycosis fungoides skin lesions. It may help people whose skin lymphoma has not responded to at least one prior standard treatment.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.